Epizyme

ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some
ESMO: It’s early days for Pfizer’s EZH2 inhibitor, but there’s a glimpse of hope for some
Fierce Biotech
ESMO
Pfizer
Ipsen
EZH2 inhibitors
Epizyme
Flag link:
Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen
Epizyme SEC filing details its desperate days in free fall before $247M sale to Ipsen
Fierce Pharma
Epizyme
SEC
M&A
Ipsen
Flag link:
Epizyme joins the queue of biotechs now handing out pink slips, conserving cash
Epizyme joins the queue of biotechs now handing out pink slips, conserving cash
Endpoints
Epizyme
layoffs
restructuring
R&D
Flag link:
Epizyme pairs real-life nurse with interactive tool to help follicular lymphoma patients navigate the tough questions
Epizyme pairs real-life nurse with interactive tool to help follicular lymphoma patients navigate the tough questions
Fierce Pharma
Epizyme
pharma marketing
follicular lymphoma
Flag link:
Big Pharma Is Going Holiday Shopping. Who's Next?
Big Pharma Is Going Holiday Shopping. Who's Next?
Motley Fool
Big Pharma
M&A
ChemoCentryx
Epizyme
Magenta Therapeutics
Flag link:
CEO Steps Down as Epizyme Finalizes 5-Year Growth Strategy
CEO Steps Down as Epizyme Finalizes 5-Year Growth Strategy
BioSpace
Epizyme
Pharma CEOs
Robert Bazemore
Flag link:
EHA: Epizyme's first-in-class multiple myeloma drug candidate inhibits tumors in mice
EHA: Epizyme's first-in-class multiple myeloma drug candidate inhibits tumors in mice
Fierce Biotech
EHA
Epizyme
Multiple Myeloma
EPZ-719
Flag link:
Fortunes diverge for solo drug launchers
Fortunes diverge for solo drug launchers
EP Vantage
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Flag link:
Epizyme's Tazverik Wins FDA Approval to Treat Follicular Lymphoma
Epizyme's Tazverik Wins FDA Approval to Treat Follicular Lymphoma
Motley Fool
Epizyme
FDA
Tazverik
follicular lymphoma
Flag link:
Epizyme eyes lucrative use for newly-launched Tazverik
Epizyme eyes lucrative use for newly-launched Tazverik
Pharmaforum
Epizyme
FDA
Tazverik
follicular lymphoma
Flag link:
Epizyme's Cancer Drug to Get Rapid FDA Review for a New Indication
Epizyme's Cancer Drug to Get Rapid FDA Review for a New Indication
Motley Fool
Epizyme
FDA
tazemetostat
follicular lymphoma
Flag link:
Epizyme drug granted approval by FDA for rare cancer
Epizyme drug granted approval by FDA for rare cancer
BioPharma Dive
Epizyme
FDA
Tazverik
Eisai
epithelioid sarcoma
Flag link:
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
Flag link:
FDA’s in-house review offers bleak assessment of Epizyme’s tazemetostat — but win or lose this cancer drug may still have a future
FDA’s in-house review offers bleak assessment of Epizyme’s tazemetostat — but win or lose this cancer drug may still have a future
Endpoints
Epizyme
FDA
tazemetostat
epithelioid sarcoma
Flag link:
The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week
The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week
Yahoo/Benzinga
Epizyme
tazemetostat
Avadel
AV001
FDA
Flag link:
Where Will Epizyme Be in 1 Year?
Where Will Epizyme Be in 1 Year?
Motley Fool
Epizyme
Flag link:
Epizyme announces FDA filing acceptance of new drug application and priority review for tazemetostat to treat epithelioid sarcoma
Epizyme announces FDA filing acceptance of new drug application and priority review for tazemetostat to treat epithelioid sarcoma
Pharmaceutical Business Review
Epizyme
FDA
tazemetostat
epithelioid sarcoma
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Flag link:
ASCO: With FDA review nearing, Epizyme shares updated sarcoma data
ASCO: With FDA review nearing, Epizyme shares updated sarcoma data
Fierce Biotech
ASCO 2019
Epizyme
clinical trials
tazemetostat
epithelioid sarcoma
Flag link:
Epizyme moves forward with cancer drug, eyes 2020 launch
Epizyme moves forward with cancer drug, eyes 2020 launch
Biopharma Dive
Epizyme
FDA
tazemetostat
epithelioid sarcoma
Flag link:

Pages